PI
CERE

PEAK6 Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

PEAK6 Investments’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,500
Closed -$359K – 4510
2024
Q1 		$359K Sell
8,500
-8,500
-50% -$357K ﹤0.01% 2675
2023
Q4 		$721K Buy
+17,000
New +$488K ﹤0.01% 2345
2023
Q3 		– Sell
-7,500
Closed -$238K – 4690
2023
Q2 		$238K Buy
+7,500
New +$230K ﹤0.01% 2767
2022
Q3 		– Sell
-7,500
Closed -$238K – 6360
2022
Q2 		$238K Buy
+7,500
New +$213K ﹤0.01% 4608

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return